Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enochian Biosciences Inc (NQ: ENOB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.7000 (2)
Ask (Size) 0.7350 (1)
Prev. Close 0.7000
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 158,717,342
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

More News

Read More
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech
Via Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of ‘Impressive’ Results from Proof-of-Concept Studies
Via Investor Brand Network
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
3 Doomed Biotech Stocks Destined for Disaster
Via InvestorPlace
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
From Enochian BioSciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
From Enochian BioSciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.